BioSpace News Archive

Veracyte, Inc . (Nasdaq: VCYT) announced new data demonstrating that a genomic signature derived from the company’s Decipher GRID database could help determine which men experiencing prostate cancer progression following radical prostatectomy (RP).

HeartBeam, Inc will hold a conference call on Thursday November 10, 2022 at 4:30 p.m. Eastern time to discuss its results for the third quarter ended September 30, 2022, and will be reviewing recent announcements, ongoing initiatives, and key 2022 and anticipated 2023 milestones.

Neogen Corporation (NASDAQ: NEOG) announced today that the Megazyme Rapid Integrated Total Dietary Fiber (RINTDF) method has been accepted by the Association of Official Analytical Chemists (“AOAC International”).

Shineco, Inc. announced that on October 21, 2022, the Company, through its wholly-owned subsidiary, Shineco Life Science Research Co., Ltd., entered into a Stock Purchase Agreement to acquire 51% of the issued equity interest of Changzhou Biowin Pharmaceutical Co., Ltd., a Chinese biotechnology company focusing on in-vitro diagnostic product research and development and high-tech biomedical products manufacturing.

RestorixHealth, the nation’s leading wound care solutions company, is pleased to announce that Jeff Bowman has joined RestorixHealth as the Division President of Post-Acute Operations.

Petros Pharmaceuticals, Inc. (Nasdaq:PTPI), a leading provider of therapeutics for men’s health, today announces the expansion of the FDA labeling for its oral erectile dysfunction (ED) drug, STENDRA (avanafil), marketed by its subsidiary, Metuchen Pharmaceuticals.

Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a life sciences company that is focused on the development of immunologic-based therapies for the prevention and treatment of disease, today announced positive results in a preclinical model of acute kidney injury (AKI), chronic kidney disease (CKD).

bioAffinity Technologies, Inc. announced the People’s Republic of China awarded a Certificate of Patent to the Company’s wholly owned subsidiary OncoSelect® for its patent “Porphyrin Compounds and Compositions Useful for Treating Cancer” that is directed to novel compounds in which porphyrins are conjugated to chemotherapeutics for selective delivery of cancer treatment.

Bryn Pharma LLC is celebrating the power of the food allergy advocacy community’s efforts to advance life-changing innovations.

Edcetera, the Eden Capital-backed provider of continuing education, exam prep, and licensing programs, today announced the acquisition of Pulse Radiology, a pre-licensure and continuing education provider that helps Radiologic Technologists (RTs) prepare for both ARRT Structured Education and Clinical Requirements.